Skip to search formSkip to main contentSkip to account menu

HDAC-42

Known as: AR-42, HDAC Inhibitor AR-42, OSU-HDAC42 
An orally available phenylbutyrate-derived histone deacetylase (HDAC) inhibitor, with potential antineoplastic activity. Upon oral administration, AR… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent Terminology

Broader (1)

Phenylbutyrates

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Histone deacetylase inhibitor AR-42 inhibits breast cancer cell growth and demonstrates a synergistic effect in combination with 5-FU.
AR-42 is a member of a novelly discovered class of phenylbutyrate-derived histone deacetylase inhibitors, and has a number of… 
2017
2017
Combined Androgen Administration and HDAC Inhibition in Experimental Cancer Cachexia
Background: Cancer cachexia impacts the majority of advanced cancer patients but no approved anti-cachexia therapeutic exits… 
2016
2016
A phase 1 study of AR-42 in patients with advanced solid tumors, including nervous system tumors.
2558Background: We have shown that AR-42, an oral pan-histone deacetylase inhibitor, has clinical activity in some hematologic… 
2016
2016
On concentration of Ar-42 in the Earth's atmosphere
Data from the DBA liquid argon ionization chamber experiment have been used to obtain an estimate on the concentration of 42Ar in… 
2014
2014
Abstract 5540: Preclinical investigation of the novel histone deacetylase (HDAC) inhibitor AR-42 in the treatment of cancer-induced cachexia
Background: Cachexia occurs in more than 50% of cancer patients. Cachexia is characterized by severe loss of weight and skeletal… 
2013
2013
Abstract 4392: Targeting HADC-2: Chemopreventive effect of OSU-HDAC42 on rat colon carcinogenesis and APCmin/+ Mice intestinal tumorigenesis.
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Epigenetic modulators particularly histone… 
2009
2009
The antitumor effects of OSU-HDAC42, a novel histone deacetylase inhibitor, in HER-2-positive breast cancer.
e14587 Background: Elevated HER-2/neu expression in primary breast tumors is associated with frequent relapse and poor prognosis… 
2009
2009
Identification of the Histone Deacetylase Inhibitor (HDACi), AR-42, as a Novel Anti-Leukemia Stem Cell Agent in Acute Myeloid Leukemia (AML).
Abstract 2070 Poster Board II-47 Despite recent progress, the majority of AML patients are refractory or relapse following… 
2006
2006
Preclinical pharmacokinetic studies with s-HDAC-42 (NSC 736012), an inhibitor of histone deacetylase, by LC-MS/MS
3091 Purpose. R, S-HDAC-42 (NSC 731438), an inhibitor of histone deacetylase, has been found to possess potent cytotoxicity in… 
2006
2006
The Novel Histone Deacetylase Inhibitor OSU-HDAC42 Has Class I and II Histone Deacetylase (HDAC) Inhibitory Activity and Represents a Novel Therapy for Chronic Lymphocytic Leukemia.
Inhibitors of histone deacetylase (HDAC) have generated major interest for the treatment of multiple cancers including B-cell… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)